

Cover Story
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Trump cuts IVF drug deal with Merck in exchange for tariff exemption
- Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer
- Science advocates organize march in DC to demand impeachment of RFK Jr.
- Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?














